FDA-Inspected Site

IMI TAMI Institute for Research and Development Ltd

2 FDA inspections are on record for IMI TAMI Institute for Research and Development Ltd in Kiryat Atta, Israel.

483· Form 483 issued

Kiryat Atta, Israel · Last updated July 11, 2026

Overview

  • 2 FDA inspections are on record.
  • 2 inspections produced a Form 483.
  • The most recent recorded inspection date is 2022-12-08.

At a glance

Inspections

2

Form 483s

2

EIRs

0

Last outcome

Form 483

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
6 Dec 2022 – 8 Dec 2022Human Drugs483View 483 →
14 Sep 2009Not recorded483On file

Observations on record

Form 483 observations cited at this site, most recent first.

8 Dec 2022
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Zachary L Stamm, Ashar P Parikh

8 Dec 2022
21 CFR 211.165(f)

Failing drug products not rejected

Cited by Zachary L Stamm, Ashar P Parikh

8 Dec 2022
21 CFR 211.194(a)(2)

Suitability of testing methods verified

Cited by Zachary L Stamm, Ashar P Parikh

8 Dec 2022
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Zachary L Stamm, Ashar P Parikh

8 Dec 2022
21 CFR 211.68(a)

Calibration/Inspection/Checking not done

Cited by Zachary L Stamm, Ashar P Parikh

Investigators

FDA investigators tied to this site in the record.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.165(f)Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)(2)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.68(a)Cited across public-safe Form 483 observations1x

Full site report

Get the verbatim findings behind this site's 2 Form 483s

Recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat